Bajaj Healthcare LimitedQ1 FY27 Results & Financial Update
Bajaj Healthcare Limited: Q1 FY27 standalone results and company financials – revenue ₹165.63 Cr, PAT ₹13.70 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Bajaj Healthcare price & chart
Market price₹338.50
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Bajaj Healthcare Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Bajaj Healthcare reported revenue from operations of Rs. 165.6 crore for the quarter ended June 30, 2026.
Gross profit reached Rs. 80.4 crore, delivering a gross margin expansion to 48.3% from 46.2% in the corresponding quarter of the previous fiscal year.
EBITDA stood at Rs. 29.6 crore, representing an EBITDA margin improvement to 17.8% compared to 17.1% previously.
Profit after tax (PAT) before exceptional items registered at Rs. 13.7 crore, reflecting a PAT margin of 8.3%.
Growth in the domestic API division offset temporary geopolitical headwinds in export markets and a slight moderation in the formulations segment.
Managing Director Anil Jain noted that operational capabilities and disciplined execution contributed to margin resilience as the fiscal year commenced.
Profit after tax was ₹13.70 Cr for the reported quarter. EPS was ₹4.06 for the reported quarter.
01 · Business model
What does Bajaj Healthcare do?
Bajaj Healthcare Limited operates as a manufacturer of active pharmaceutical ingredients (APIs), intermediates, and finished pharmaceutical formulations.
Established in 1993, the company produces pharmaceutical products and nutraceuticals across various medical therapies for domestic and international markets.
Its manufacturing infrastructure includes state-of-the-art facilities engineered to comply with regulatory standards across both regulated and emerging global geographies.
The customer footprint extends across Europe, the USA, Australia, the Middle East, and South America.
02 · Historical context
What shaped the business before this quarter
Established in 1993, Bajaj Healthcare built its operations around the manufacturing of APIs, intermediates, and formulations.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹165.63 Cr |
| Total income | ₹166.44 Cr |
| Profit before tax | ₹16.46 Cr |
| Profit after tax | ₹13.70 Cr |
| EPS | ₹4.06 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 8.3% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 9.9% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹0.81 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Domestic API sales grew to Rs. 92.3 crore compared to Rs. 72.6 crore in Q1 FY26, supported by volume expansion across key products.
API export sales moderated slightly to Rs. 50.1 crore from Rs. 52.2 crore in Q1 FY26 due to temporary disruptions caused by geopolitical conditions in West Asia.
Formulations revenue registered Rs. 23.3 crore compared to Rs. 24.1 crore in Q1 FY26, representing a temporary slowdown that management expects to normalize as FY27 progresses.
What drove margins
An enhanced product mix drove gross margin expansion to 48.3% for Q1 FY27 from 46.2% in Q1 FY26.
Disciplined execution and operational leverage contributed to an improvement in EBITDA margin to 17.8% from 17.1% in the year-ago period.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The API division recorded 14.0% year-on-year growth and 13.5% sequential growth, propelled by healthy underlying demand.
The formulations segment experienced a minor pullback during the quarter, with management anticipating normalization as broader market conditions improve.
Geography and market mix
The company advanced its regulatory standing in Europe and the United Kingdom by filing two additional Certificate of Suitability (CEP) applications during the quarter.
06 · Capacity, projects & execution
What is being built, commissioned or delivered
Projects, capex and execution
The expanded state-of-the-art research and development centre at Savli commenced operations during the quarter, enhancing product development and process innovation capabilities.
07 · Strategy & new businesses
How the company is trying to change its growth mix
The company secured SEC recommendation for the manufacture and marketing of Cenobamate Tablets, positioning itself as the first in India to achieve this milestone for the anti-seizure medication.
08 · Reported developments
What changed operationally
Secured Subject Expert Committee (SEC) recommendation for manufacturing and marketing Cenobamate Tablets for partial-onset seizures in adults.
Reached a cumulative total of twelve CEP filings, comprising eight approved certificates and four under active review.
09 · Pressure points & risks
What is not going smoothly
API exports experienced temporary delivery and logistics disruptions stemming from geopolitical tensions in West Asia.
10 · Beyond the numbers
What changed beyond the numbers
Reported update
Regulatory milestone
Achieved first-in-India SEC recommendation for Cenobamate Tablets for treating adult partial-onset seizures.
Reported update
CEP filings update
Filed two new CEP applications during the quarter, lifting the total number of CEP filings to 12, with 8 approvals secured to date.
11 · Key Q&A
The quarter, answered directly
What does Bajaj Healthcare do?
Bajaj Healthcare Limited operates as a manufacturer of active pharmaceutical ingredients (APIs), intermediates, and finished pharmaceutical formulations.
What is the clearest takeaway from Q1 FY27?
Bajaj Healthcare reported revenue from operations of Rs. 165.6 crore for the quarter ended June 30, 2026.
What drove revenue or demand?
Domestic API sales grew to Rs. 92.3 crore compared to Rs. 72.6 crore in Q1 FY26, supported by volume expansion across key products.
What mattered most for margins or profitability?
An enhanced product mix drove gross margin expansion to 48.3% for Q1 FY27 from 46.2% in Q1 FY26.
What changed operationally beyond the headline numbers?
The expanded state-of-the-art research and development centre at Savli commenced operations during the quarter, enhancing product development and process innovation capabilities.
What are the main pressure points disclosed for the quarter?
API exports experienced temporary delivery and logistics disruptions stemming from geopolitical tensions in West Asia.
12 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
13 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Cenobamate commercial rollout: Track further regulatory clearance and subsequent commercial launch progress for Cenobamate Tablets.
- 02
Formulations normalization: Monitor whether formulations revenue and export shipments recover from regional West Asian disruptions as FY27 progresses.
- 03
Savli R&D output: Observe the translation of the newly operational Savli R&D centre into new product filings and process enhancements.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.